The Regulatory Reality of 2026: What Actually Changed In late 2023, the FDA moved 19 peptides, including BPC-157, to what's known as "Category 2" status under its framework for bulk drug substances used in compounding, identifying them as substances that "may present significant safety risks." The concern, as stated in FDA guidance, centered on the limited large-scale human data and questions about immunogenicity
These are general educational frameworks, not personalized prescriptions
BPC-157 10 mg 135.00 From driving your body and mind towards peak performance to reducing everyday inflammation and supporting gut health, research suggests BPC-157 is an ally for those looking to unlock their natural potential and benefit from its restorative capabilities
Its important to discuss any concerns or health issues with a clinician
GHK-Cu demonstrates reproducible antioxidant effects across multiple experimental platforms, including isolated cell systems and whole-animal injury models